Skip to main content
SpringerLink
Log in
Book cover

Cancer Neurology in Clinical Practice pp 3–6Cite as

The Prevalence and Impact of Neurologic Disease in Cancer

  • Chapter

  • 164 Accesses

Abstract

Interest in neuro-oncology has increased rapidly over the last 30 years, and subspecialties have emerged within the fields of neurology, neurosurgery, radiotherapy, and medical oncology. Each of these specialties deals with different aspects and has made important contributions to this new branch of oncology. The principal practitioners of medical neuro-oncology, in contrast to surgical neuro-oncology, are neurologists and occasionally medical oncologists. Medical neuro-oncologists focus their attention on diagnosis, nonsurgical therapy (including symptomatic treatments and chemotherapy), and follow-up of neuro-oncological disorders. By training, neurologists have the asset of being well-equipped to localize and interpret neurological signs and symptoms and are familiar with diagnosing and treating disorders of the nervous system. Among the oncological subspecialties, neuro-oncology has become a recognized area. Thus, the field of neuro-oncology can be viewed from two different angles, either as a subspecialty of one of the mother specialties, be it neurology, neurosurgery, radiotherapy, or medical oncology or, alternatively, as a subspecialty of oncology.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   74.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Gilbert M, Armstrong T, Meyers C. Issues in assessing and interpreting quality of life in patients with malignant glioma. Semin Oncol 2000; 27 (3 Suppl 6): 20–26.

    PubMed  CAS  Google Scholar 

  2. Meyers CA, Hess KR, Yung WK, Levin VA. Cognitive function as a predictor of survival in patients with recurrent malignant glioma. J Clin Oncol 2000; 18 (3): 646–650.

    PubMed  CAS  Google Scholar 

  3. Osoba D, Aaronson NK, Muller M et al. Effect of neurological dysfunction on health-related quality of life in patients with high-grade glioma. J Neurooncol 1997; 34 (3): 263–278.

    Article  PubMed  CAS  Google Scholar 

  4. Driesse MJ, Esandi MC, Kros JM et al. Intra-CSF administered recombinant adenovirus causes an immune response-mediated toxicity. Gene Ther 2000; 7 (16): 1401–1409.

    Article  PubMed  CAS  Google Scholar 

  5. Okada H, Pollack IF, Lotze MT et al. Gene therapy of malignant gliomas: a phase I study of IL-4-HS V-TK gene-modified autologous tumor to elicit an immune response. Hum Gene Ther 2000; 11 (4): 637–653.

    Article  PubMed  CAS  Google Scholar 

  6. Duffner PK, Cohen ME. Recent developments in pediatric neuro-oncology. Cancer 1986; 58 (2 Suppl): 561–568.

    Article  PubMed  CAS  Google Scholar 

  7. Levin VA. Neuro-oncology: an overview. Arch Neurol 1999; 56 (4): 401–104.

    Article  PubMed  CAS  Google Scholar 

  8. Posner JB. The role of the neurologist in the management of cancer. Am J Med 1978; 65 (1): 4–6.

    Article  PubMed  CAS  Google Scholar 

  9. Hildebrand J, Sahmoud T, Mignolet F, Brucher JM, Afra D. Adjuvant therapy with dibromodulcitol and BCNU increases survival of adults with malignant gliomas. EORTC Brain Tumor Group. Neurology 1994; 44 (8): 1479–1483.

    CAS  Google Scholar 

  10. Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 2000; 83 (5): 588–593.

    Article  PubMed  CAS  Google Scholar 

  11. Cairncross JG. Aggressive oligodendroglioma: a chemosensitive tumor. Recent Results Cancer Res 1994; 135: 127–133.

    Article  PubMed  CAS  Google Scholar 

  12. Chamberlain MC. Leptomeningeal metastases:, a review of evaluation and treatment. J Neurooncol 1998, 37 (3): 271–284.

    Article  PubMed  CAS  Google Scholar 

  13. DeAngelis LM, Yahalom J, Thaler HT, Kher U. Combined modality therapy for primary CNS lymphoma. J Clin Oncol 1992; 10 (4): 635–643.

    PubMed  CAS  Google Scholar 

  14. Siegal T. Leptomeningeal metastases: rationale for systemic chemotherapy or what is the role of intra-CSF-chemotherapy? J Neurooncol 1998; 38 (2–3): 151–157.

    Article  PubMed  CAS  Google Scholar 

  15. Clouston PD, DeAngelis LM, Posner JB. The spectrum of neurological disease in patients with systemic cancer. Ann Neurol 1992, 31 (3); 268–273.

    Article  PubMed  CAS  Google Scholar 

  16. Patchell RA, Tibbs PA, Regine WF, et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 1998; 280 (17): 1485–1489.

    Article  PubMed  CAS  Google Scholar 

  17. Vecht CJ, Haaxma-Reiche H, Noordijk EM, et al. Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery? Ann Neurol 1993; 33 (6): 583–590.

    Article  PubMed  CAS  Google Scholar 

  18. Vecht CJ, Hovestadt A, Verbiest HB, van Vliet JJ, van Putten WL. Dose-effect relationship of dexamethasone on Karnofsky performance in metastatic brain tumors: a randomized study of doses of 4, 8, and 16 mg per day. Neurology 1994; 44 (4): 675–680.

    CAS  Google Scholar 

  19. Darnell JC, Albert ML, Darnell RB. Cdr2, a target antigen of naturally occuring human tumor immunity, is widely expressed in gynecological tumors. Cancer Res 2000; 60 (8): 2136–2139.

    PubMed  CAS  Google Scholar 

  20. Delattre JY, Ameri A, Albuquerque L, Poisson M. Late cerebral complications of radiotherapy. Ann Med Interne (Paris) 1994; 145 (2): 125–132.

    CAS  Google Scholar 

  21. Taphoorn MJ, Schiphorst AK, Snoek FJ, et al. Cognitive functions and quality of life in patients with low-grade gliomas: the impact of radiotherapy. Ann Neurol 1994; 36 (1): 48–54.

    Article  PubMed  CAS  Google Scholar 

  22. Vigliani MC, Duyckaerts C, Hauw JJ, Poisson M, Magdelenat H, Delattre JY. Dementia following treatment of brain tumors with radiotherapy administered alone or in combination with nitrosoureabased chemotherapy: a clinical and pathological study. J Neurooncol 1999; 41 (2): 137–149.

    Article  PubMed  CAS  Google Scholar 

  23. Hilkens PH, Verweij J, Vecht CJ, Stoter G, van den Bent MJ. Clinical characteristics of severe peripheral neuropathy induced by docetaxel (Taxotere). Ann Oncol 1997; 8 (2): 187–190.

    Article  PubMed  CAS  Google Scholar 

  24. Jeremic B, Djuric L, Mijatovic L. Incidence of radiation myelitis of the cervical spinal cord at doses of 5500 cGy or greater. Cancer 1991; 68 (10): 2138–2141.

    Article  PubMed  CAS  Google Scholar 

  25. DeAngelis LM, Delattre JY, Posner JB. Radiation-induced dementia in patients cured of brain metastases. Neurology 1989; 39 (6): 789–796.

    Article  PubMed  CAS  Google Scholar 

  26. Halberg FE, Kramer JH, Moore IM, Wara WM, Matthay KK, Ablin AR. Prophylactic cranial irradiation dose effects on late cognitive function in children treated for acute lymphoblastic leukemia. Int J Radiat Oncol Biol Phys 1992; 22 (1): 13–16.

    Article  PubMed  CAS  Google Scholar 

  27. van der Hoop RG, Vecht CJ, van der Burg ME, et al. Prevention of cisplatin neurotoxicity with an ACTH (4–9) analogue in patients with ovarian cancer. N Engl J Med 1990; 322 (2): 89–94.

    Article  PubMed  Google Scholar 

  28. Windebank AJ, Smith AG, Russell JW. The effect of nerve growth factor, ciliary neurotrophic factor, and ACTH analogs on cisplatin neurotoxicity in vitro. Neurology 1994; 44 (3 Pt 1): 488–494.

    Article  PubMed  CAS  Google Scholar 

  29. Foley KM. Advances in cancer pain. Arch Neurol 1999; 56 (4): 413–417.

    Article  PubMed  CAS  Google Scholar 

  30. Portenoy RK, Lesage P. Management of cancer pain. Lancet 1999; 353 (9165): 1695–1700.

    Article  PubMed  CAS  Google Scholar 

  31. Caraceni A, Portenoy RK. An international survey of cancer pain characteristics and syndromes. IASP Task Force on Cancer Pain. International Association for the Study of Pain. Pain 1999, 82 (3); 263–274.

    Article  Google Scholar 

  32. Voltz R, Borasio GD. Palliative therapy in the terminal stage of neurological disease. J Neurol 1997; 244 Suppl 4: S2 - S10.

    Google Scholar 

Download references

Authors
  1. Charles J. Vecht MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Neurology, University of Virginia Medical Center, Charlottesville, VA, USA

    David Schiff MD

  2. Center for Neuro-Oncology Dana-Farber Cancer Institute; and Department of Neurology, Brigham and Women’s Hospital, Boston, MA, USA

    Patrick Y. Wen MD

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer Science+Business Media New York

About this chapter

Cite this chapter

Vecht, C.J. (2003). The Prevalence and Impact of Neurologic Disease in Cancer. In: Schiff, D., Wen, P.Y. (eds) Cancer Neurology in Clinical Practice. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-317-0_1

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-317-0_1

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4757-4703-4

  • Online ISBN: 978-1-59259-317-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation